Pathstone Family Office’s Prestige Consumer Healthcare PBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-5,169
Closed -$325K 1431
2022
Q4
$325K Buy
5,169
+429
+9% +$24.6K ﹤0.01% 1229
2022
Q3
$237K Buy
+4,740
New +$262K ﹤0.01% 1291
2017
Q2
Sell
-7
Closed 574
2017
Q1
$0 Buy
+7
New +$386 ﹤0.01% 608
2015
Q4
Sell
-745
Closed -$34K 144
2015
Q3
$34K Sell
745
-413
-36% -$19.5K 0.09% 50
2015
Q2
$54K Hold
1,158
0.09% 34
2015
Q1
$50K Sell
1,158
-1,160
-50% -$44.2K 0.08% 45
2014
Q4
$80K Hold
2,318
0.27% 22
2014
Q3
$75K Hold
2,318
0.23% 30
2014
Q2
$79K Buy
+2,318
New +$74.2K 0.22% 23

Other funds holding PBH

Pathstone Family Office's PBH Position: Q1 2023 in Review

Pathstone Family Office sold out of Prestige Consumer Healthcare (PBH) in Q1 2023, closing a stake of 5,169 shares — an estimated $325K sold.

Pathstone Family Office first reported a position in PBH in Q2 2014 and held it in 9 quarters. The position peaked at $325K in Q4 2022. 283 funds tracked by Wall St. Rank hold PBH as of Q1 2023.

  • Pathstone Family Office reported no remaining Prestige Consumer Healthcare position as of Q1 2023 after selling out during the quarter.
  • Pathstone Family Office sold 5,169 Prestige Consumer Healthcare shares in Q1 2023, an estimated $325K.
  • Pathstone Family Office first reported a position in Prestige Consumer Healthcare in Q2 2014 and held it in 9 quarters.
  • Pathstone Family Office's Prestige Consumer Healthcare position peaked at $325K in Q4 2022.
  • 283 funds tracked by Wall St. Rank held Prestige Consumer Healthcare as of Q1 2023.

Based on Pathstone Family Office's 13F filing for Q1 2023, filed 15 May 2023.